ADVA-OPTICAL-NETWORKING
14.10.2021 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that i3D.net has deployed its FSP 3000 TeraFlex™ to enhance the experience of the 50 million online gamers that i3D.net serves every day. The technology enables the leading hosting solutions provider for the gaming industry to meet rising data demand and customer expectation by significantly increasing capacity and reducing latency in its global transport network. ADVA’s highly flexible solution enables i3D.net to harness previously unused spectrum, optimizing all optical paths and unlocking new value in its existing fiber infrastructure. The TeraFlex™ terminal will also benefit i3D.net’s enterprise customers, who will be able to leverage low-latency video conferencing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005058/en/
“As one of the world’s leading high-performance hosting providers, we’re constantly striving to deliver an unbeatable experience for end users. That means investing in the most advanced technology on the market. With our new infrastructure built on the ADVA FSP 3000 TeraFlex™ , we’re removing any bottlenecks by massively increasing the capacity of our network. And, thanks to its ultra-flexible coherent interfaces with fractional QAM, it ensures maximum data throughput over every link,” said Edwin Verwoerd, VP, engineering, i3D.net. “Low latency is our business, and that’s precisely what our new solution offers. It enables us to provide a winning edge to both players and businesses.“
i3D.net’s specific configuration of the ADVA FSP 3000 TeraFlex™ is able to carry up to 400Gbit/s of data per wavelength and 800Gbit/s per sled. This open and ultra-flexible 1RU terminal uses software-defined fractional QAM modulation and adaptive baud rate capabilities. As well as significantly boosting the capacity of i3D.net’s worldwide infrastructure, the ADVA FSP 3000 TeraFlex™ ensures the lowest cost per bit for every fiber path. What’s more, it offers advanced streaming telemetry. This provides operators with real-time performance data, helping them to ensure the highest levels of availability and quality of service for end users. The new solution also features other components of ADVA’s FSP 3000 open optical transport solution , including FSP 3000 QuadFlex™ optical terminals.
“Our FSP 3000 TeraFlex™ will be a vital tool for i3D.net. It will be key to seizing new opportunities during the global gaming boom and providing unprecedented levels of quality for its customers. The innovative terminal offers excellent space- and power-efficiency while maximizing fiber utilization. With its flexible bandwidth modulation, it ensures optimal performance even over long-distance links. That’s why our high-performance TeraFlex™ is ideal for supporting satisfying, immersive gaming,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “It’s great to see another major operator harnessing our TeraFlex™ technology to unlock extra value in its infrastructure. Spread across six continents, i3D.net’s network will now deliver even more for its customers.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About i3D.net
i3D.net – a Ubisoft company, is one of the leading providers of high-performance hosting and global infrastructure services. We operate a global low-latency network with thousands of servers spread over 40+ point of presence on 6 continents. i3D.net excels in the gaming market and hosts a variety of AAA games. Our mission is to bring the lowest latency to as many users around the world as possible, with the goals of reaching 1 billion users on our platforms by 2025. For more information visit www.i3d.net .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005058/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom